HOME > BUSINESS
BUSINESS
- Ohara’s High-Need Pediatric Cancer Drug in Limbo 2 Years after Approval due to GMP Issue
February 15, 2019
- Kowa to Reshuffle Pharma Business in April, Launching New Company for LLP Operations
February 15, 2019
- Armed with Positive Data, G47Δ Could Reach Filing in May as Japan’s 1st Oncolytic Virus
February 14, 2019
- Recordati Ratcheting Up Japan Biz, Set to Enrich Rare Disease Portfolio
February 14, 2019
- Upbeat Global Brands Drive Otsuka Sales in 2018
February 14, 2019
- GSK Japan’s Fauchet Bows Out as Chairman
February 14, 2019
- Avanir, DOJ Reach Agreement over Nuedexta Marketing Activity Case
February 14, 2019
- Eisai Files Fycompa in Europe for Pediatric Use
February 14, 2019
- MSD Files Keytruda/Inlyta Combo in Japan as 1st-Line Therapy for RCC
February 14, 2019
- Generic Player Ohara Looks to Morph into Innovative Drug Maker, with Focus on Oncology
February 13, 2019
- Takeda’s Adcetris Gets European OK for 1st-Line Stage IV Hodgkin’s Lymphoma
February 13, 2019
- Astellas/Pfizer Unveil Positive Xtandi Data for Hormone-Sensitive Prostate Cancer
February 13, 2019
- Oncolys in Talks with Checkpoint Drug Makers for Telomelysin: President
February 12, 2019
- US Latuda Sales Might Fall Short as Lawsuits Weigh: Sumitomo Dainippon Chief
February 12, 2019
- Xofluza Top Seller in Japan in January: Encise Snapshot
February 12, 2019
- Mochida Seeks Label Expansion for Dinagest in Japan
February 12, 2019
- Pfizer Initiates Voluntary Recall of Exforge Generics after Discovery of Carcinogenic Substances Above Limits
February 12, 2019
- Sumitomo Dainippon, Aikomi Join Forces for Research on Medical Devices to Relieve BPSD
February 12, 2019
- Ethical Drug Sales Down 4.5% in December: Crecon
February 8, 2019
- SymBio Targets 11.8 Billion Yen Sales in 2022 under New 4-Year Biz Plan
February 8, 2019
ページ
On paper, things should be looking up for Japan’s pharmaceutical wholesalers. Industry expectations are mounting that the average gap between NHI and market prices will narrow further in FY2026 from the previous year’s record low of 4.8%.A shrinking gap should…
Tariffs have been a defining feature of US trade policy under President Donald Trump’s second administration. Since Trump unveiled his “reciprocal” tariff policy in April 2025, the landscape has shifted repeatedly.In February 2026, the US Supreme Court invalidated tariffs imposed…
